BidaskClub upgraded shares of Pieris Pharmaceuticals (NASDAQ:PIRS) from a sell rating to a hold rating in a research report report published on Tuesday morning.
Separately, HC Wainwright set a $12.00 target price on shares of Pieris Pharmaceuticals and gave the stock a buy rating in a research note on Thursday, August 9th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Pieris Pharmaceuticals currently has a consensus rating of Buy and an average price target of $12.33.
Shares of NASDAQ PIRS opened at $5.23 on Tuesday. The company has a market capitalization of $302.59 million, a PE ratio of -13.00 and a beta of 1.62. Pieris Pharmaceuticals has a 52-week low of $4.43 and a 52-week high of $9.75.
In related news, Director Christopher P. Kiritsy acquired 5,000 shares of the stock in a transaction that occurred on Friday, September 14th. The shares were bought at an average price of $5.11 per share, for a total transaction of $25,550.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at $51,100. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 5.07% of the stock is owned by corporate insiders.
Institutional investors have recently modified their holdings of the stock. A.R.T. Advisors LLC bought a new position in Pieris Pharmaceuticals during the first quarter valued at approximately $103,000. Public Employees Retirement System of Ohio purchased a new stake in Pieris Pharmaceuticals during the second quarter valued at approximately $110,000. Marshall Wace LLP purchased a new stake in Pieris Pharmaceuticals during the second quarter valued at approximately $118,000. Fox Run Management L.L.C. purchased a new stake in Pieris Pharmaceuticals during the second quarter valued at approximately $124,000. Finally, MetLife Investment Advisors LLC purchased a new stake in Pieris Pharmaceuticals during the first quarter valued at approximately $141,000. Institutional investors own 64.93% of the company’s stock.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
See Also: What is the S&P 500 Index?
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.